|
PI 3-kinase p110beta: a new target for antithrombotic therapy
Nat Med. 2005 May; 11(5):507-14. Epub 2005 Abr 17
Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hugh |
|
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction11/04/2005
Arch Intern Med. 2005 Abr; 165(7):784-9.
Buresly K, Eisenberg MJ, Zhang X, Pilote L165 |
|
Angiogenesis inhibitors found within the haemostasis pathway
J Cell Mol Med. 2005 Abr; 9(2):286-302.
Staton CA, Lewis CE |
|
A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI).
J Thromb Haemost. 2005 Abr; 3(4):651-8.
Dahm AE, Andersen TO, Rosendaal F, Sandset PM. |
|
Thrombophilia in children with cystic fibrosis.
Pediatr Pulmonol. 2005 Abr; 39(4):306-10.
Balfour-Lynn IM, MalbonK, Burman JF, Davidson SJ. |
|
The 46C-->T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis.
J Thromb Haemost. 2005 Mar; 3(3):597-9.
Bertina RM, Poort SR, Vos HL, Rosendaal FR. |
|
Molecular mechanisms underlying the proangiogenic effect of factor XIII.
Arterioscler Thromb Vasc Biol. 2005 Mar; 25(3):526-32.
Dardik R, Loscalzo J, Eskaraev R, Inbal A. |
|
Assessment of Cardiac Structure and Left Atrial Appendage Functions in Primary Antiphospholipid Syndrome. A Transesophageal Echocardiographic Study.
Stroke. 2005 Mar; 35(3):592-6.
Erdogan D, Taner Goren M, Diz-Kucukkaya R, Inanc M. |
|
Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis.
ThrombHaemost. 2005 Mar; 93(3):411-3.
Al-Shanqeeti A, van Hylckama Vlieg A, Berntorp E, Rosendaal FR, Broze GJ Jr. |
|
Antithrombotic therapy in hypertension: a Cochrane Systematic review.
J Hum Hypertens. 2005 Mar; 19(3):185-96.
Felmeden DC, Lip GY. |
|
Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies.
J ThrombHaemost. 2005 Feb; 3(2):292-9.
DEN Heijer M, Lewington S, Clarke R. |
|
Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis.
J ThrombHaemost. 2005 Feb; 3(2):405-7.
Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom JC. |
|
Management of thrombosis in cancer: primary prevention and secondary prophylaxis.
Br J Haematol. 2005 Feb; 3(2):292-9.
Lee AY. |
|
Coagulation Factor XIII VaI34Leu Polymorphism in Patients with Small Vessel Disease or Primary Intracerebral Hemorrhage.
Cerebrovasc Dis. 2005 Ene; 19(3):165-170.
Slowik A, Dziedzic T, Pera J, Figlewicz DA, Szczudlik A. |
|
Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial.
Ann Intern Med. 2005 Ene; 142(1):1-10.
Menendez-Jandula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, Bonfill X, Fontcuberta J. |
|
Summaries for patients. Patient self-management versus clinic management of oral blood thinner therapy.
Ann Intern Med. 2005 Ene; 142(1):I14-.
- |
|
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.
J Am CollCardiol. 2005 Ene; 45(1):25-9.
Marin F, Gonzalez-Conejero R, Lee KW, Corral J, Roldan V, Lopez F, Sogorb F, Caturla J, Lip GY, Vicente V. |
|
Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
Am J Cardiovasc Drugs. 2005 Ene; 5(5):307-18.
Duffy B, Bhatt DL. |
|
Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke
Drugs. 2005 Ene; 65(4):461-71.
Weinberger J |
|
New perspectives on von Willebrand factor functions in hemostasis and thrombosis.
Semin Hematol. 2005 Ene; 42(1):5-14.
Mendolicchio GL, Ruggeri ZM. |
